Listen Now

This is the latest episode of the free DDW podcast, “China’s opportunities for global drug discovery breakthroughs”. It covers three articles written for Volume 22, Issue 4 – Fall 2021 of DDW, narrated by DDW Multimedia Editor Megan Thomas. They are called “Is China entering a new phase for drug discovery?”, “Finding drug discovery opportunities in China” and “Why biotech in China offers global opportunities”. In the first article, DDW Publishing Director Lu Rahman explores the Chinese pharmaceutical landscape and what the new era of drug discovery is starting to look like in the country. In the second article, Dr Henry Li, CSO of Crown Bioscience, examines cycles of innovation in the Chinese life sciences industry and how they provide opportunities for global drug discovery breakthroughs. In the third article, Sy Chyi Yeoh, Director of Business Development at global regulatory service provider ELC Group, explains why the biotech sector in China is worth watching and offers advice for those keen to take advantage.

This is the latest episode of the free DDW podcast, “Revealing the magic of cell therapy”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW magazine. They are called “The magic of cell therapy” and “Cellular assays to bridge the gap in immunogenicity prediction”. In the first article, Marjie Hadad talks to cell therapy expert and Kadimastem CEO Asaf Shiloni about the potential of cell therapy. In the second article, Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.

This is the latest episode of the free DDW podcast, “How to improve process while maintaining quality”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “How can the bioprocess industry respond to cost and maintain quality?” and “RNA: a coming-of-age technology for viral vaccines”.  In the first article, Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality.   In the second article, Dr Andy Lane, Commercial Director at The Native Antigen Company, discusses the development of a new generation of vaccine platforms that can be rapidly adapted to novel threats on-demand and at low cost.   You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW podcast, “Now is the time for the transformation of clinical trials”. It covers two narrated articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Clinical trials, the pandemic and technology” and “Pharma and the benefits of Real World Data ”.  In the first article, Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data. In the second article, Karen Ooms, Executive Vice President and Head of Statistics with Quanticate, argues that analysing data from real-life patients has finally come of age.  You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW podcast, “The pursuit of better cancer treatments”. It covers two narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. They are called “The personal touch: the scientist making an impact in cancer research” and “Biotech’s pursuit of next-generation CAR-T”.  In the first article, Lu Rahman speaks with Martyn Hiscox, uncovering his passion, dedication and the personal reason for developing cell therapy treatments for cancer. In the second article, Pierre-Louis Joffrin from Mogrify examines immunotherapies including an assessment of the next generation of stem cell derived products.  You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This is the latest episode of the free DDW podcast, “Mini-library approach delivers an arsenal in drug development pipeline”. It covers a narrated article written for Volume 22, Issue 3 –Summer 2021 of DDW. In the article, Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than 100 compounds. You can also find The Drug Discovery World Podcast on Spotify, Google Playand Apple Podcasts.

This is the latest episode of the free DDW podcast, “What does gene-based medicine have to offer?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW.   The articles are called “Lipidomics in biomedical research: chance and challenges” and “Exploring gene-based medicine’s true potential”.  In the first article, Afrisha Anderson, a Product Manager at Merck KGaA, discusses the opportunities and challenges in lipidomics. In the second article, Christopher Doyle, PhD, Director, IBC Services at WCG, explains why he thinks vaccines for infectious diseases are just the tip of the iceberg when thinking about the promise of gene-based medicines. 

Podcast: Is customisation healthcare’s secret weapon?  This is the latest episode of the free DDW podcast, “Is customisation healthcare’s secret weapon?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW.  The articles are called “Optimising vaccine production through customisation” and “Exploring iPSCs for individual and population health applications”.  In the first article, “Optimising vaccine production through customisation”, John Yoshi Shyu, Ph.D. Corning Life Sciences offers an expert view on the topic. In the second article, Brad Hamilton, Founder and Chief Science Officer at GoodCell, examines the potential of induced Pluripotent Stem Cells.  You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

This episode covers three narrated articles written for Volume 22, Issue 3 – Summer 2021 and Volume 22, Issue 4 – Fall 2021 of DDW.   The articles are called “The benefits of bioinformatics in genomics sequencing” and “LIMs vs ELNs – what does your lab need?”, for which Part I and Part II were published separately across DDW issues.  Dr Bongcho Kim is the new CEO of Macrogen Europe, a Netherlands-based provider of genomic sequencing services. Dr Kim’s appointment comes at a time of sustained growth for the company, which is benefitting from the rapidly expanding sequencing market. In the first article, he talks to Lu Rahman and explains the important role of bioinformatics in genomics.   The second and third article are in two parts. Researchers often ask whether a LIMS or an ELN is right for them. In this two-part series, Barry Bunin, PhD, CEO at Collaborative Drug Discovery, offers a guide to understanding what a LIMS is, and how it differs from other scientific data management systems. 

The latest episode of the free DDW podcast is titled “A comprehensive analysis of European biotech”. It covers three narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW, read by Megan Thomas.   The articles are “Innovation and opportunity within Europe’s biotech sector”, “Europe’s emerging biotechs: Challenges, opportunities and funding”, and “Why Switzerland continues to punch above its weight as global biotech hub”.  In the first article, Lu Rahman introduces a slice of European biotech expertise. In the second, John Macdonald of ICON examines the European biotech sector’s expertise, opportunities and potential for growth. In the third, Lu Rahman spoke to Michael Altorfer of the Swiss Biotech Association, Jan Lucht of scienceindustries, Claude Joris of BioAlps, and Carole Delauney of swiss

The latest episode of the free DDW podcast is titled“What do we know about lab automation?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW, read by Megan Thomas.   The articles are “What has 2020 taught us about lab automation?” and “Enhancing drug discovery with laboratory informatics and automation”.   In 2021, the first article looked back on 2020 and Dr Patrick Courtney from SiLA consortium, Burkhard Schaefer from SiLA consortium and ASTM AnIML, and Oliver Peter from Idorsia Pharmaceuticals outlined the importance of automation in the face of global disease.   In the second article, Laura Marozsan, Scientific Marketing Specialist at Thermo Fisher Scientific, outlines the benefits of automation in drug discovery.  

The latest DDW Sitting Down With sponsored podcast features Dominque Bröhl and Evert-Jan Uringa, Scientific Program Managers at Taconic Biosciences who discuss how mouse model generation can be accelerated without any loss of quality. The generation of genetically engineered custom mouse models can be a lengthy process that conflicts with the general time constraints of the drug discovery and development industry. Finding ways to shorten the time to create new mouse models is tempting but carries the risk of trading short timelines for poor quality. Taconic Biosciences developed the ExpressMODEL® portfolio of products to achieve the industry’s fastest timelines to study cohort without compromising quality, whether embryonic stem cell (ESC), CRISPR, or random integration transgenic (RITg) methodology is used to generate a mouse model. Listen in to learn how ExpressMODEL® accelerates timelines and which benefits it brings to your drug discovery and development program.

This is the latest episode of the free DDW podcast, “What can we learn from the genome?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW and read aloud by Megan Thomas.   The articles are called “Reproducibility in single cell genomic analysis” and “The road to global pharmacogenomics”.  

This episode is titled “From here to there: What lies ahead for drug discovery”, which covers two articles written for Volume 22, Issue 3 – Summer 2021 of DDW. They are called “The complexity of disease biology gives opportunities for drug discovery” and “The human touch: the benefits of real-world evidence”. In the first article, Steve Gardner, CEO PrecisionLife, examines the lack of return on investment for pharmaceutical R&D and the huge pockets of unmet medical need in common chronic disorders. In the second article, Lu Rahman looks at the growing role of real world evidence and its benefits in the fight against Covid-19.

Medidata technology has helped to bring COVID-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Decentralised clinical trials, described as the ‘new normal’ and the future of clinical research, harness remote technologies to enable patients to participate in clinical trials from their home or preferred location, decreasing patient burden and offering greater flexibility as well as increasing the reach to patients around the world. Lisa Moneymaker is the Senior Vice President of Clinical Operations Technologies for Medidata Solutions. She has over 20 years of pharma, biotech, and medical device industry experience, delivering complex systems solutions in support of excellence in clinical trial execution. Paul O’Donohoe is Senior Director, eCOA Product and Science at Medidata. He is responsible for developing the company's scientific expertise for electronic clinical outcome assessments, and mobile health in clinical trials, and supports internal teams and sponsors around the implementation of industry and regulatory best practices in studies using eCOA. Listen to this podcast to find out more about why decentralised clinical trials are becoming increasingly significant, how the pandemic has affected the clinical trials space, the importance of the patient experience and what clinical trials will look like in the future.

The latest free-to-listen DDW podcast episode is titled “Therapeutics: Changing the way we treat disease”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “Avoiding double strand breaks on the CRISPR path to therapeutic discovery” and “The power of precision medicine”.  In the first article, Nicola McCarthy from Horizon Discovery explains: Now a key pillar in the early stages of therapeutics development, the limitations of introducing a DNA double strand break mean that workflows are broadening away from CRISPR–Cas as a gene knockout technology and towards platforms that enable genetic modulation and safer genetic alterations.   In the second article, DDW Editor Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we treat disease. 

High-throughput screens are a recognised hit-finding process but the use of an integrated discipline approach is key to maximising the output from such a screening methodology. In the first article, Ian Linney and Scott Maidment from Charles River describe the value of integration of medicinal chemistry in this method.   Thanks to continued advances in genetic engineering, investigators often find they can obtain the most relevant mouse model for their research by commissioning the custom generation of a model that best meets their need—whether it’s modelling a disease state, validating a gene target of interest, or testing a drug candidate in vivo. Caroline Horizny from Taconic Biosciences discusses this in the second article. 

The articles are called “The new synthesis: How synthetic DNA technology is changing drug discovery” and “In vitro drug interaction data critical in drug repurposing”. The first was written by Dr Tim Brears, CEO of Evonetix and Dr Raquel Sanches-Kuiper, Director of Biology at Evonetix. The second was written by Madison Knapp, Marketing Communications Specialist, and Dr. Brian Ogilvie, Vice President of Scientific Consulting, at SEKISUI XenoTech. In “The new synthesis: How synthetic DNA technology is changing drug discovery”, Dr Tim Brears and Dr Raquel Sanches-Kuiper explore applications of synthetic DNA in drug discovery and development, the benefits and limitations of current methods, and the opportunities offered by emerging DNA synthesis technologies. In the wake of Covid-19 interest in repurposing a drug for a different indication to the one it was developed for has been high. In “In vitro drug interaction data critical in drug repurposing”, Madison Knapp and Dr. Brian Ogilvie offer insight into the process.

In the first article, DDW Editor Lu Rahman takes look at some of the latest imaging innovations available and how it can benefit drug target identification and drug discovery research. In the second, Farah Patell-Socha, PhD, VP Research Products tells Lu Rahman about some of the company’s groundbreaking work in this field and the benefits it is creating for disease modelling and drug discovery. 

The latest free-to-listen DDW podcast episode covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine, narrated by DDW’s Megan Thomas.  These articles are titled: “Antibody therapeutics: the other race for immunity against SARS-CoV2” and “Synthesising new solutions for small molecule antibodies”.  In the first article, Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. In the second, Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors.